NHWA(SZ:002262) 智通财经网·2025-12-24 13:49Core Viewpoint - Enhua Pharmaceutical has entered into exclusive commercial cooperation agreements with Green Leaf Pharmaceutical and its subsidiary, allowing Enhua to promote and sell three long-acting injectable antipsychotic products in mainland China, marking a significant strategic partnership in the CNS field [1][2]. Group 1: Agreement Details - Enhua's subsidiary, Jiangsu Enhua Hexin Pharmaceutical Marketing Co., Ltd., will receive exclusive rights to promote and sell three products: Risperidone microspheres (Riketu®), Paliperidone palmitate injection (Ruibailai®), and Paliperidone palmitate injection (Meibiru®) [1]. - Enhua will pay a one-time non-refundable licensing fee of $20 million to Green Leaf Pharmaceutical and Green Leaf Jiaao [1]. - The agreement stipulates that Enhua must achieve a minimum sales target of 2.7 billion RMB (approximately $400 million) for the licensed products between 2026 and 2035 [1]. Group 2: Strategic Importance - The exclusive authorization for these three long-acting injectables creates a differentiated product portfolio that addresses the treatment needs of schizophrenia patients at all stages of the disease [2]. - This strategic collaboration between two leading companies in the CNS field is expected to enhance the market presence of these products in primary healthcare centers, facilitating standardized treatment for more patients and reducing the burden of the disease [2].